Al-Moamary Mohamed S, Al-Lehebi Riyad, Idrees Majdy M, Zeitouni Mohammed O
Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Pulmonary Section, Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.
Ann Thorac Med. 2022 Oct-Dec;17(4):185-188. doi: 10.4103/atm.atm_341_22. Epub 2022 Oct 7.
Asthma control is the main goal of management. Unfortunately, most asthma patients with moderate-severe asthma remain uncontrolled despite receiving standard treatment of inhaled corticosteroids (ICS) with long-acting β2 agonists (LABA). The addition of long-acting antimuscarinic agents (LAMA) has been shown to improve different aspects of asthma control, including symptoms, lung functions, and probably exacerbations. Such an option could be considered for low-T2 asthma phenotype. Umeclidinium and glycopyrronium bromide are other LAMA agents that have been recently made available in combination with ICS and LABA in single-inhaler triple therapy (SITT) devices. Here, we discuss the position of SITT as a new novel therapeutic option in asthma management and its clinical benefits, potential cost saving, and improved compliance.
哮喘控制是管理的主要目标。不幸的是，大多数中重度哮喘患者尽管接受了吸入性糖皮质激素（ICS）与长效β2受体激动剂（LABA）的标准治疗，但仍未得到控制。添加长效抗胆碱能药物（LAMA）已被证明可在哮喘控制的不同方面有所改善，包括症状、肺功能，可能还包括病情加重情况。对于低T2哮喘表型可考虑这一选择。乌美溴铵和格隆溴铵是其他LAMA药物，最近已可与ICS和LABA联合用于单吸入器三联疗法（SITT）装置中。在此，我们讨论SITT作为哮喘管理中一种新的治疗选择的地位及其临床益处、潜在的成本节约和依从性改善情况。
